Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5578678 | 0.99 | OPRM1 (0.48) | OPRM1OPRK1OPRL1SIGMAR1DRD2 | |
| SCHEMBL5578435 | 0.90 | CTSS (0.43) | OPRM1OPRK1OPRL1KCNH2CTSS | |
| SCHEMBL5578609 | 0.86 | OPRM1 (0.52) | OPRM1OPRK1OPRL1SIGMAR1DRD2 | |
| SCHEMBL13000278 | 0.85 | NOTUM (0.50) | OPRM1OPRK1OPRL1SIGMAR1DRD2 | |
| SCHEMBL5579084 | 0.84 | OPRM1 (0.48) | OPRM1OPRK1OPRL1SIGMAR1DRD2 | |
| SCHEMBL12084839 | 0.84 | OPRL1 (0.58) | OPRM1OPRK1OPRL1SIGMAR1CTSS | |
| SCHEMBL5578762 | 0.84 | OPRM1 (0.50) | OPRM1OPRK1OPRL1SIGMAR1DRD2 | |
| SCHEMBL12084309 | 0.83 | OPRL1 (0.56) | OPRM1OPRK1OPRL1SIGMAR1OPRD1 | |
| SCHEMBL5578544 | 0.83 | SIGMAR1 (0.47) | OPRM1OPRK1OPRL1SIGMAR1DRD2 | |
| SCHEMBL5579000 | 0.83 | OPRM1 (0.49) | OPRM1OPRK1OPRL1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | claimed |
| WO-2005063745-A9 | NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF | ARENA PHARM INC (US) | 2007-02-01 | — | — | WO | claimed |
| US-20020077456-A1 | Process for producing an amide compound | NIHON MEDI-PHYSICS COMPANY, LIMITED (JP) | 2002-06-20 | — | — | US | claimed |
| US-6403056-B1 | ADMINISTERING AGENT; APPLYING ULTRASONIC FREQUENCY | IMARX THERAPEUTICS, INC. | 2002-06-11 | — | — | US | claimed |
| US-11213598-B2 | Labeled probe and methods of use | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-01-04 | — | — | US | disclosed |
| US-20180369409-A1 | TUMOR-SPECIFIC PAYLOAD DELIVERY AND IMMUNE ACTIVATION USING A HUMAN ANTIBODY TARGETING A HIGHLY SPECIFIC TUMOR CELL SURFACE ANTIGEN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-12-27 | — | — | US | disclosed |
| US-20180353628-A1 | Labeled Probe and Methods of Use | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2018-12-13 | — | — | US | disclosed |
| US-20140010757-A1 | IMAGING METHODS USING ENGINEERED INTEGRIN BINDING PEPTIDES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-01-09 | — | — | US | disclosed |
| US-20070259815-A1 | Albumin fusion proteins | HUMAN GENOME SCIENCES, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2005063745-A9 | NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF | ARENA PHARM INC (US) | 2007-02-01 | — | — | WO | disclosed |
| US-6723318-B1 | EXTRACORPOREAL REMOVAL OF CIRCULATING TOXIC AGENTS | MITRA MEDICAL TECHNOLOGY AB (SE) | 2004-04-20 | — | — | US | disclosed |
| US-20030120204-A1 | Oxygen delivery agents and uses for the same | CEREVAST THERAPEUTICS, INC. | 2003-06-26 | — | — | US | disclosed |
| US-6548047-B1 | Using lecithin, cephalin filled with gases; scanning; medical diagnosis | BRISTOL-MYERS SQUIBB MEDICAL IMAGING, INC. | 2003-04-15 | — | — | US | disclosed |
| US-6537246-B1 | Blood substitutes comprising a fluorinated gas and a stabilizing aqueous solution containing lipids; the perfluorocarbon compounds, perfluorooctylbromide and perfluorohexane, are preferred | IMARX THERAPEUTICS, INC. | 2003-03-25 | — | — | US | disclosed |
| US-6416740-B1 | DELIVERY STABILIZED MICROSPHERES COMPRISED OF PHOSPHATIDYL-CHOLINES, PHOSPHATIDYLETHANOLAMINES, AND PHOSPHATIDIC ACIDS AND CONTAINING THERAPEUTIC AGENTS (SUCH AS TAXOL), AND RUPTURING THE SPHERES WITH ULTRASOUND; TARGETED DELIVERY | BRISTOL-MYERS SQUIBB MEDICAL IMAGING, INC. | 2002-07-09 | — | — | US | disclosed |
| US-6403056-B1 | ADMINISTERING AGENT; APPLYING ULTRASONIC FREQUENCY | IMARX THERAPEUTICS, INC. | 2002-06-11 | — | — | US | disclosed |
| US-20010031243-A1 | Novel methods of ultrasound treatment using gas or gaseous precursor-filled compositions | IMARX PHARMACEUTICAL CORP. | 2001-10-18 | — | — | US | disclosed |
| US-20010018072-A1 | Solid matrix therapeutic compositions | IMARX THERAPEUTICS, INC. | 2001-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031243-A1 | Novel methods of ultrasound treatment using gas or gaseous precursor-filled compositions | SON, HYOU1, GCG | OPRM1 1371/4885OPRK1 2776/4885OPRL1 1820/4885 |
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | REN, AVPR2, RECQL | OPRM1 630/4885OPRK1 131/4885OPRL1 240/4885 |
| US-20020077456-A1 | Process for producing an amide compound | NAAA, ACMSD, CPS1 | OPRM1 2981/4885OPRK1 2843/4885OPRL1 2614/4885 |
| US-20010018072-A1 | Solid matrix therapeutic compositions | MMP7, MMP1, MMP17 | OPRM1 3187/4885OPRK1 3173/4885OPRL1 2745/4885 |
| US-20180369409-A1 | TUMOR-SPECIFIC PAYLOAD DELIVERY AND IMMUNE ACTIVATION USING A HUMAN ANTIBODY TARGETING A HIGHLY SPECIFIC TUMOR CELL SURFACE ANTIGEN | ALPP, HLA-A, ALPI | OPRM1 4754/4885OPRK1 4776/4885OPRL1 3943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.